{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:01:36Z","timestamp":1767974496920,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.autrev.2015.04.014","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T23:09:07Z","timestamp":1430608147000},"page":"769-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease\u2014Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases"],"prefix":"10.1016","volume":"14","author":[{"given":"Valder\u00edlio Feij\u00f3","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"de Souza Meirelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussara de Almeida Lima","family":"Kochen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sender J.","family":"Miszputen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio Vieira","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad\u00e9rson Osmar Mour\u00e3o Cintra","family":"Dami\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Gustavo","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Arnone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Ferreira Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Pires Amaral","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Vicente E.","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.04.014_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMp1107285","article-title":"Developing the nation's biosimilars program","volume":"365","author":"Kozlowski","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.04.014_bb0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.biologicals.2011.06.014","article-title":"A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products","volume":"39","author":"Schiestl","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2015.04.014_bb0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14712591003796553","article-title":"Biosimilars: current status and future directions","volume":"10","author":"Roger","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2015.04.014_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpb.2009.02.014","article-title":"Biosimilars\u2014science, status, and strategic perspective","volume":"72","author":"Kresse","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.autrev.2015.04.014_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2015.04.014_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2015.04.014_bb0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.det.2014.09.009","article-title":"Ten years on: the impact of biologics on the practice of dermatology","volume":"33","author":"Leonardi","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.autrev.2015.04.014_bb0045","doi-asserted-by":"crossref","first-page":"e97077","DOI":"10.1371\/journal.pone.0097077","article-title":"Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation\u2014an economic analysis based on the ESPOIR cohort","volume":"9","author":"Chevreul","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.04.014_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1590\/S0482-50042010000300002","article-title":"Are we prepared to prescribe biosimilars?","volume":"50","author":"Azevedo","year":"2010","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2011.08.034","article-title":"Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know","volume":"66","author":"Strober","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0060","author":"Food and Drug Administration"},{"key":"10.1016\/j.autrev.2015.04.014_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5639\/gabij.2014.0303.032","article-title":"Recommendations for the regulation of biosimilars and their implementation in Latin America","volume":"3","author":"Azevedo","year":"2014","journal-title":"GaBI J"},{"key":"10.1016\/j.autrev.2015.04.014_bb0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nbt.2322","article-title":"In support of the European Union biosimilar framework","volume":"30","author":"Schneider","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drudis.2011.08.001","article-title":"The regulatory framework of biosimilars in the European Union","volume":"17","author":"Minghetti","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2015.04.014_bb0080","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2015.04.014_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11523-011-0192-7","article-title":"Biosimilars and market access: a question of comparability and costs?","volume":"7","author":"Simoens","year":"2012","journal-title":"Target Oncol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0090","author":"World Health Organization"},{"key":"10.1016\/j.autrev.2015.04.014_bb0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10067-015-2887-0","article-title":"Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view","volume":"4","author":"Pineda","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/14712598.2013.783560","article-title":"Pharmacovigilance and biosimilars: considerations, needs and challenges","volume":"13","author":"Casadevall","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2015.04.014_bb0105","first-page":"129","article-title":"Biosimilars require scientifically reliable comparative clinical data","volume":"53","author":"Azevedo","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1677-54492010000300009","article-title":"Non-inferiority clinical trials: concepts and issues","volume":"9","author":"Pinto","year":"2010","journal-title":"J Vasc Bras"},{"key":"10.1016\/j.autrev.2015.04.014_bb0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biologicals.2011.06.004","article-title":"Biosimilars clinical development program: confirmatory clinical trials: a virtual\/simulated case study comparing equivalence and non-inferiority approaches","volume":"39","author":"Fletcher","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2015.04.014_bb0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0125","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"D\u00f6rner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0135","first-page":"60","article-title":"The Portuguese Society of Rheumatology position paper on the use of biosimilars","volume":"39","author":"Fonseca","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.autrev.2015.04.014_bb0140","first-page":"1583","article-title":"Considerations about the approval of biosimilar formulations (biogenerics) in Chile. [Interchangeability of biological drugs: considerations about the approval of biogeneric formulations in Chile]","volume":"134","author":"Saavedra","year":"2006","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.autrev.2015.04.014_bb0145","author":"Food and Drug Administration"},{"key":"10.1016\/j.autrev.2015.04.014_bb0150","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria"},{"key":"10.1016\/j.autrev.2015.04.014_bb0155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5639\/gabij.2014.0303.032","article-title":"Recommendations for the regulation of biosimilars and their implementation in Latin America","volume":"3","author":"Azevedo","year":"2014","journal-title":"GAbi J"},{"key":"10.1016\/j.autrev.2015.04.014_bb0160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4161\/mabs.25864","article-title":"Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry","volume":"5","author":"Beck","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2015.04.014_bb0165","article-title":"Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation","author":"Scott","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2015.04.014_bb0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.autrev.2015.04.014_bb0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2014.02.007","article-title":"Biosimilars: in support of extrapolation of indications","volume":"8","author":"Ebbers","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.crohns.2013.12.002","article-title":"Biosimilars in Crohn's disease","volume":"8","author":"Scheinberg","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1155\/2013\/634176","article-title":"Subsequent entry biologics\u2014opportunities and challenges","volume":"27","author":"Ghosh","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0195","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2015.04.014_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNFalpha for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2015.04.014_bb0205","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2015.04.014_bb0210","doi-asserted-by":"crossref","first-page":"567e71","DOI":"10.1155\/2013\/327120","article-title":"Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics","volume":"27","author":"Devlin","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0215","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Registro brasileiro de biol\u00f3gicos: processo de implementa\u00e7\u00e3o e resultados preliminares do BiobadaBrasil","volume":"51","author":"TITTON","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.autrev.2015.04.014_bb0220","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2014.01.051","article-title":"Putting the value into biosimilar decision making: the judgment value criteria","volume":"13","author":"Mendes de Abreu","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T13:28:25Z","timestamp":1566653305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1568997215001068"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.04.014","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease\u2014Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}